CNS Pharmaceuticals, Inc.
CNSP
$1.13
$0.00490.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.66% | 23.20% | 19.65% | -17.99% | -48.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.51% | 24.15% | -37.20% | -28.04% | 4.77% |
| Operating Income | 40.51% | -24.15% | 37.20% | 28.04% | -4.77% |
| Income Before Tax | 40.91% | -23.95% | 37.06% | 28.13% | -4.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.91% | -23.95% | 37.06% | 28.13% | -4.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.91% | -23.95% | 37.06% | 28.13% | -4.64% |
| EBIT | 40.51% | -24.15% | 37.20% | 28.04% | -4.77% |
| EBITDA | 40.52% | -24.16% | 37.20% | 28.04% | -4.80% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |